We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Angiotensin Peptide Slows Cancer by Blocking New Blood Vessel Formation

By LabMedica International staff writers
Posted on 07 Sep 2009
Cancer researchers reported identifying a small peptide that slows cancer growth by inhibiting the process that leads to the formation new blood vessels.

Investigators from Wake Forest University School of Medicine (Winston-Salem, NC, USA) had shown previously that the seven amino acid peptide angiotensin-(1-7) [Ang-(1-7)] slowed the growth of human lung cancer cells growing in culture and reduced the size of human lung tumor xenografts in immunocompromised mice.

In the current study, which was published in June 9, 2009, online edition of the journal Molecular Cancer Therapeutics, the investigators extended their work by injecting Ang-(1-7) or a saline control into mice human carrying human lung cancer tumors. More...
After six weeks they found that the tumors in the animals treated with Ang-(1-7) were reduced in size, while the tumors in the saline-treated animals continued to grow. Ultimately, the tumors in the treated mice weighed nearly 60% less than the tumors in the control animals.

Other experiments carried out in tissue culture and in chick embryos revealed that Ang-(1-7) inhibited growth of new vascular tissue. This effect could be completely blocked by the specific Ang-(1-7) receptor antagonist [d-proline7]-Ang-(1-7), suggesting that these biological actions were mediated by an Ang-(1-7) receptor.

"Because it is a peptide, it is very small and can be made very easily,” said contributing author Dr. Patricia E. Gallagher, professor of molecular genetics at Wake Forest University School of Medicine. "We sometimes like to say we are the aspirin of cancer therapy. If you are diagnosed with lung cancer today, you have got a 15% chance of surviving five years--and that is just devastating. Those other 85 people--85%--they are not going to see their kids graduate. They are not going to see their children get married.”

Related Links:
Wake Forest University School of Medicine


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.